Spectrum of ANCA-Associated Disorders According to Serological Phenotype in Routine Care: Retrospective Case Series of 209 Patients
DOI:
https://doi.org/10.12970/2310-9874.2013.01.02.3Keywords:
ANCA, vasculitis, anti-MPO, anti-PR3, IIF, ELISA, ANCA associated vasculitides.Abstract
Objective: To summarize the experience of three years of positive ANCA (anti-neutrophil cytoplasmic antibodies) testing in a single university based hospital. We describe the clinical features according to ANCA phenotype of patients who did and did not have ANCA- associated vasculitis (AAV).
Methods: We did a review of all samples tested for ANCA in a 3 year-period (2005-2007). Each sample was tested by indirect immunofluorescence (IIF) and enzyme-linked-immunosorbent assay (ELISA). Sera were considered as positive for ANCA testing if either IIF or ELISA for MPO or PR3 antigen specificity was positive. Patients were considered as having AAV on established diagnostic criteria and algorithms.
Results: The positive ANCA population consisted in 209 patients, 54 were classified in the AAV group and 155 patients constituted the “Others” group. The typically most relevant ANCA phenotypes (C-ANCA/anti-PR3+ and P-ANCA/anti-MPO+) were detected in 90 % (49/54) of patients in the AAV group and only 10% (15/155) of the “Others” group (p < 0.001). Among the latter none developed AAV during follow-up. Positive IIF alone was found in 4% (2/54) of the AAV group and in 68% (105/155) of the “Others” group (p < 0.001). In patients without AAV, positive IIF alone or positive ELISA with negative IIF represented the main ANCA pattern.
Conclusion: In routine clinical practice, most patients with positive ANCA testing do not have AAV. The typical ANCA pattern (C-ANCA/anti-PR3+ or P-ANCA/anti-MPO+) remains a strong predictor of AAV in patients with a high level of suspicion for systemic vasculitis. In other cases, ANCA positivity should be interpreted with extreme caution.
References
Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006; 368: 404-18. http://dx.doi.org/10.1016/S0140-6736(06)69114-9
Chen M, Kallenberg CG. ANCA-associated vasculitides: advances in pathogenesis and treatment. Nat Rev Rheumatol 2010; 6: 653-64. http://dx.doi.org/10.1038/nrrheum.2010.158
Jennette JC, Falk RJ. New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies. Curr Opin Rheumatol 2008; 20: 55-60. http://dx.doi.org/10.1097/BOR.0b013e3282f16c0a
Gómez-Puerta JA, Bosch X. Anti-neutrophil cytoplasmic antibody pathogenesis in small-vessel vasculitis: an update. Am J Pathol 2009; 175: 1790-8. http://dx.doi.org/10.2353/ajpath.2009.090533
Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000; 43: 2025-33. http://dx.doi.org/10.1002/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O
Terrier B, Saadoun D, Sène D, et al. Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides. Ann Rheum Dis 2009; 68: 1564-71. http://dx.doi.org/10.1136/ard.2008.094714
Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis – a meta-analysis. Rheumatology (Oxford) 2012; 51: 100-9. http://dx.doi.org/10.1093/rheumatology/ker280
Mandl LA, Solomon DH, Smith FL, Lew RA, Katz JN, Shmer-ling RH. Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis: can test-ordering guidelines improve diagnostic accuracy? Arch Intern Med 2002; 162: 1509-14. http://dx.doi.org/10.1001/archinte.162.13.1509
Fries JF, Hunder GG, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 1990; 33: 1135-6. http://dx.doi.org/10.1002/art.1780330812
Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92. http://dx.doi.org/10.1002/art.1780370206
Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013; 65: 1-11. http://dx.doi.org/10.1002/art.37715
Chen M, Yu F, Wang SX, Zou WZ, Zhao MH, Wang HY. Antineutrophil cytoplasmic autoantibody-negative pauci-immune crescentic glomerulonephritis. J Am Soc Nephrol 2007; 18: 599-605. http://dx.doi.org/10.1681/ASN.2006091021
Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42: 421-30. http://dx.doi.org/10.1002/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6
Desplat-Jégo S, Johanet C, Escande A, et al. Update on Anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study. World J Gastroenterol 2007; 13: 2312-8.
Schönermarck U, Lamprecht P, Csernok E, Gross WL. Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. Rheumatology (Oxford) 2001; 40: 178-84. http://dx.doi.org/10.1093/rheumatology/40.2.178
Cui Z, Zhao MH, Segelmark M, Hellmark T. Natural autoantibodies to myeloperoxidase, proteinase 3, and the glomerular basement membrane are present in normal individuals. Kidney Int 2010; 78: 590-7. http://dx.doi.org/10.1038/ki.2010.198
Savige J, Gillis D, Benson E, et al. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol 1999; 111: 507-13.
Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007; 66: 222-7. http://dx.doi.org/10.1136/ard.2006.054593
Savige J, Pollock W, Trevisin M. What do antineutrophil cytoplasmic antibodies (ANCA) tell us? Best Pract Res Clin Rheumatol 2005; 19: 263-76. http://dx.doi.org/10.1016/j.berh.2004.10.003
Geffriaud-Ricouard C, Noël LH, Chauveau D, Houhou S, Grünfeld JP, Lesavre P. Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients. Clin Nephrol 1993; 39: 125-36.
Stone JH, Talor M, Stebbing J, et al. Test characteristics of immunofluorescence and ELISA tests in 856 consecutive patients with possible ANCA-associated conditions. Arthritis Care Res 2000; 13: 424-34. http://dx.doi.org/10.1002/1529-0131(200012)13:6<424::AID-ART14>3.0.CO;2-Q
Vizjak A, Nagode B, Rott T, et al. Antineutrophil cytoplasmic autoantibodies-antigen specificity and associated diseases. Wien Klin Wochenschr 2000; 112: 665-70.
Tsiveriotis K, Tsirogianni A, Pipi E, Souferos K, Papasteriades C. Antineutrophil cytoplasmic antibodies testing in a large cohort of unselected Greek patients. Autoimmune Diseases 2011. http://dx.doi.org/10.4061/2011/626495
Choi HK, Liu S, Merkel PA, Colditz GA, Niles JL. Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimy-eloperoxidase antibodies. J Rheumatol 2001; 28: 1584-90.
Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic anti-bodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998; 53: 743-53. http://dx.doi.org/10.1046/j.1523-1755.1998.00807.x
Gallicchio MC, Savige JA. Detection of anti-myeloperoxidase and anti-elastase antibodies in vasculitides and infections. Clin Exp Immunol 1991; 84: 232-7. http://dx.doi.org/10.1111/j.1365-2249.1991.tb08154.x
Pradhan VD, Badakere SS, Iyer YS, Kumar R, Almeida AF. A study of anti-neutrophil cytoplasm antibodies in systemic vasculitis and other related disorders. J Postgrad Med 2003; 49: 5-9. http://dx.doi.org/10.4103/0022-3859.936
Russell KA, Wiegert E, Schroeder DR, Homburger HA, Specks U. Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. Clin Immunol 2002; 103: 196-203. http://dx.doi.org/10.1006/clim.2001.5200
Savige J, Davies D, Falk RJ, Jennette JC, Wiik A. Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features. Kidney Int 2000; 57: 846-62. http://dx.doi.org/10.1046/j.1523-1755.2000.057003846.x
Bosch X, Font J, Mirapeix E, Revert L, Urbano-Márquez A, Ingelmo M. Anti-neutrophil cytoplasmic autoantibodies (ANCA): antigenic specificities and clinical associations. Adv Exp Med Biol 1993; 336: 281-6. http://dx.doi.org/10.1007/978-1-4757-9182-2_42
Manolova I, Dantcheva M. Antineutrophil cytoplasmic antibodies in Bulgarian patients with rheumatoid arthritis: characterization and clinical associations. Rheumatol Int 2005; 26: 107-14. http://dx.doi.org/10.1007/s00296-004-0517-2
Merkel PA, Polisson RP, Chang Y, Skates SJ, Niles JL. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 1997; 126: 866-73. http://dx.doi.org/10.7326/0003-4819-126-11-199706010-00003
Calvo Romero JM, Romero Requena J, Arévalo Lorido JC, et al. Antineutrophil cytoplasmic antibodies (ANCA): clinico-pathologic correlations in a series of 82 cases. An Med Interna 2002; 19: 7-10.
Edgar JD, McMillan SA, Bruce IN, Conlan SK. An audit of ANCA in routine clinical practice. Postgrad Med J 1995; 71: 605-12. http://dx.doi.org/10.1136/pgmj.71.840.605
Sghiri R, Meddeb H, Bouguila J, Jarray et al. Antineutrophil cytoplasmic antibodies and associated diseases. Pathol Biol (Paris) 2009; 57: 398-402. http://dx.doi.org/10.1016/j.patbio.2008.07.019
Pollock W, Jovanovich S, Savige J. Antineutrophil cytoplasmic antibody (ANCA) testing of routine sera varies in different laboratories but concordance is greater for cytoplasmic fluorescence (C-ANCA) and myeloperoxidase specificity (MPO-ANCA). J Immunol Methods 2009; 347: 19-23. http://dx.doi.org/10.1016/j.jim.2009.05.008
Trevisin M, Pollock W, Dimech W, et al. Antigen-specific ANCA ELISAs have different sensitivities for active and treated vasculitis and for nonvasculitic disease. Am J Clin Pathol 2008; 129: 42-53. http://dx.doi.org/10.1309/F6L4C48RHFMT4AAU
Vermeersch P, Vervaeke S, Blockmans D, et al. Determination of anti-neutrophil cytoplasmic antibodies in small vessel vasculitis: Comparative analysis of different strategies. Clin Chim Acta 2008; 397: 77-81. http://dx.doi.org/10.1016/j.cca.2008.07.026
Xin G, Zhao MH, Wang HY. Detection rate and antigenic specificities of antineutrophil cytoplasmic antibodies in chinese patients with clinically suspected vasculitis. Clin Diagn Lab Immunol 2004; 11: 559-62.
Stone JH, Wegener's Granulomatosis Etanercept Trial Research Group. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 2003; 48: 2299-309. http://dx.doi.org/10.1002/art.11075
Robinson PC, Steele RH. Appropriateness of antineutrophil cytoplasmic antibody testing in a tertiary hospital. J Clin Pathol 2009; 62: 743-5. http://dx.doi.org/10.1136/jcp.2009.064485
Sinclair D, Saas M, Stevens JM. The effect of a symptom related "gating policy" on ANCA requests in routine clinical practice. J Clin Pathol 2004; 57: 131-4. http://dx.doi.org/10.1136/jcp.2003.8052
Hogan SL, Cooper GS, Savitz DA, et al. Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case-control study. Clin J Am Soc Nephrol 2007; 2: 290-9. http://dx.doi.org/10.2215/CJN.03501006
Knight A, Ekbom A, Brandt L, Askling J. What is the significance in routine care of c-ANCA/PR3-ANCA in the absence of systemic vasculitis? A case series. Clin Exp Rheumatol 2008; 26: S53-6.
McAdoo SP, Hall A, Levy J, Salama AD, Pusey CD. Proteinase-3 antineutrophil cytoplasm antibody positivity in patients without primary systemic vasculitis. J Clin Rheumatol 2012; 18: 336-40. http://dx.doi.org/10.1097/RHU.0b013e31826d2005
Bonaci-Nikolic B, Andrejevic S, Pavlovic M, Dimcic Z, Ivanovic B, Nikolic M. Prolonged infections associated with antineutrophil cytoplasmic antibodies specific to proteinase 3 and myeloperoxidase: diagnostic and therapeutic challenge. Clin Rheumatol 2010; 29: 893-904. http://dx.doi.org/10.1007/s10067-010-1424-4
Savige J, Dimech W, Fritzler M, et al. International Group for Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol 2003; 120: 312-8. http://dx.doi.org/10.1309/WAEPADW0K4LPUHFN
Cohen Tervaert JW, Damoiseaux J. Fifty years of antineutrophil cytoplasmic antibodies (ANCA) testing: do we need to revise the international consensus statement on testing and reporting on ANCA? APMIS Suppl 2009; 127: 55-9. http://dx.doi.org/10.1111/j.1600-0463.2009.02478.x
Rao JK, Weinberger M, Oddone EZ, Allen NB, Landsman P, Feussner JR. The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis. Ann Intern Med 1995; 123: 925-32. http://dx.doi.org/10.7326/0003-4819-123-12-199512150-00005